www.metlife.com<\/a>.<\/p>\n\nMetLife\u2019s definitions of non-GAAP and other financial measures discussed in this news release may differ from those used by other companies:<\/p>\n
Adjusted earnings and related measures<\/i><\/b><\/p>\n\n- \nadjusted earnings;<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders;<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders on a constant currency basis;<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders, excluding total notable items;<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis;<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders per diluted common share;<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders on a constant currency basis per diluted common share;<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders, excluding total notable items per diluted common share; and<\/p>\n<\/li>\n
- \nadjusted earnings available to common shareholders, excluding total notable items, on a constant currency basis per diluted common share.<\/p>\n<\/li>\n<\/ul>\n
\nThese measures are used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings and components of, or other financial measures based on, adjusted earnings are also MetLife\u2019s GAAP measures of segment performance. Adjusted earnings and other financial measures based on adjusted earnings are also the measures by which MetLife senior management\u2019s and many other employees\u2019 performance is evaluated for the purposes of determining their compensation under applicable compensation plans. Adjusted earnings and other financial measures based on adjusted earnings allow analysis of MetLife’s performance relative to its business plan and facilitate comparisons to industry results.<\/p>\n
\nEffective January 1, 2023, MetLife adopted ASU 2018-12, Financial Services – Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, as amended (“LDTI”), with a transition date of January 1, 2021, which impacted the calculation of adjusted earnings. Due to the adoption of LDTI, the measurement model was simplified for DAC and VOBA, and most embedded derivatives were reclassified as market risk benefits. As a result, MetLife updated its calculation of adjusted earnings to remove certain adjustments related to the amortization of DAC, VOBA and related intangibles and adjusted for changes in measurement of certain guarantees. Under LDTI, adjusted earnings excludes changes in fair value associated with market risk benefits, changes in discount rates on certain annuitization guarantees, losses at contract inception for certain single premium business, and asymmetrical accounting associated with in-force reinsurance. All periods presented herein reflect the updated calculation of adjusted earnings.<\/p>\n
\nAdjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. Adjusted earnings available to common shareholders is defined as adjusted earnings less preferred stock dividends.<\/p>\n
Adjusted revenues and adjusted expenses<\/i><\/b><\/p>\n
\nThese financial measures, along with the related adjusted premiums, fees and other revenues, focus on our primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP.<\/p>\n
\nMarket volatility can have a significant impact on MetLife\u2019s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities and (ii) market value adjustments.<\/p>\n
\nAsymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings:<\/p>\n
\n- \nNet investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment (“Investment hedge adjustments”).<\/p>\n<\/li>\n
- \nOther revenues include settlements of foreign currency earnings hedges.<\/p>\n<\/li>\n
- \nPolicyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits, (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, and (iii) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts.<\/p>\n<\/li>\n
- \nInterest credited to policyholder account balances excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments.<\/p>\n<\/li>\n<\/ul>\n
\nDivested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP.<\/p>\n
\nOther adjustments are made to the line items indicated in calculating adjusted earnings:<\/p>\n
\n- \nNet investment income and interest credited to policyholder account balances excludes certain amounts related to contractholder-directed equity securities (“Unit-linked contract income”) and (“Unit-linked contract costs”).<\/p>\n<\/li>\n
- \nOther revenues include fee revenue on synthetic GICs accounted for as freestanding derivatives.<\/p>\n<\/li>\n
- \nOther revenues exclude and other expenses include fees received in connection with services provided under transition service agreements.<\/p>\n<\/li>\n
- \nOther expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives.<\/p>\n<\/li>\n<\/ul>\n
\nAdjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance.<\/p>\n
\nThe tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from MetLife’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms.<\/p>\n
\nIn addition, adjusted earnings available to common shareholders excludes the impact of preferred stock redemption premium which is reported as a reduction to net income (loss) available to MetLife, Inc.\u2019s common shareholders.<\/p>\n
Investment portfolio gains (losses) and derivative gains (losses)<\/i><\/b><\/p>\n
\nThese are measures of investment and hedging activity. Investment portfolio gains (losses) principally excludes amounts that are reported within net investment gains (losses) but do not relate to the performance of the investment portfolio, such as gains (losses) on sales and divestitures of businesses, as well as investment portfolio gains (losses) of divested businesses. Derivative gains (losses) principally excludes earned income on derivatives and amortization of premium on derivatives, where such derivatives are either hedges of investments or are used to replicate certain investments, and where such derivatives do not qualify for hedge accounting. This earned income and amortization of premium is reported within adjusted earnings and not within derivative gains (losses).<\/p>\n
Return on equity and related measures<\/i><\/b><\/p>\n\n- \nTotal MetLife, Inc.\u2019s common stockholders\u2019 equity, excluding AOCI other than FCTA: total MetLife, Inc.\u2019s common stockholders\u2019 equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses) and defined benefit plans adjustment, components of AOCI, net of income tax.<\/p>\n<\/li>\n
- \nTotal MetLife, Inc.\u2019s common stockholders\u2019 equity, excluding total notable items (excludes AOCI other than FCTA): total MetLife, Inc.\u2019s common stockholders\u2019 equity, excluding the net unrealized investment gains (losses), future policy benefits discount rate remeasurement gains (losses), market risk benefits instrument-specific credit risk remeasurement gains (losses), defined benefit plans adjustment, components of AOCI, and total notable items, net of income tax.<\/p>\n<\/li>\n
- \nReturn on MetLife, Inc.\u2019s common stockholders\u2019 equity: net income (loss) available to MetLife, Inc.\u2019s common shareholders divided by MetLife, Inc.\u2019s average common stockholders\u2019 equity.<\/p>\n<\/li>\n
- \nAdjusted return on MetLife, Inc.’s common stockholders’ equity: adjusted earnings available to common shareholders divided by MetLife, Inc.’s average common stockholders’ equity.<\/p>\n<\/li>\n
- \nAdjusted return on MetLife, Inc.’s common stockholders’ equity, excluding AOCI other than FCTA: adjusted earnings available to common shareholders divided by MetLife, Inc.’s average common stockholders’ equity, excluding AOCI other than FCTA.<\/p>\n<\/li>\n
- \nAdjusted return on MetLife, Inc.’s common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA): adjusted earnings available to common shareholders, excluding total notable items, divided by MetLife, Inc.’s average common stockholders’ equity, excluding total notable items (excludes AOCI other than FCTA).<\/p>\n<\/li>\n<\/ul>\n
\nThe above measures represent a level of equity consistent with the view that, in the ordinary course of business, MetLife does not plan to sell most investments for the sole purpose of realizing gains or losses.<\/p>\n
Expense ratio, direct expense ratio, adjusted expense ratio and related measures<\/i><\/b><\/p>\n\n- \nExpense ratio: other expenses, net of capitalization of DAC, divided by premiums, fees and other revenues.<\/p>\n<\/li>\n
- \nDirect expense ratio: adjusted direct expenses, divided by adjusted premiums, fees and other revenues.<\/p>\n<\/li>\n
- \nDirect expense ratio, excluding total notable items related to direct expenses and PRT: adjusted direct expenses, excluding total notable items related to direct expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.<\/p>\n<\/li>\n
- \nAdjusted expense ratio: adjusted other expenses, net of adjusted capitalization of DAC, divided by adjusted premiums, fees and other revenues.<\/p>\n<\/li>\n
- \nAdjusted expense ratio, excluding total notable items related to adjusted other expenses and PRT: adjusted other expenses, net of adjusted capitalization of DAC, excluding total notable items related to adjusted other expenses, divided by adjusted premiums, fees and other revenues, excluding PRT.<\/p>\n<\/li>\n<\/ul>\n
Asia General account (GA)<\/i> assets under management (GA AUM) and related measures<\/i><\/b><\/p>\n
\nAsia GA AUM is used by MetLife to describe assets in its Asia GA investment portfolio which are actively managed and stated at estimated fair value. Asia GA AUM is comprised of Asia GA total investments, the portion of the Asia GA investment portfolio classified within assets held-for-sale and cash and cash equivalents, excluding policy loans, contractholder-directed equity securities, fair value option securities and certain other invested assets, as substantially all of these assets are not actively managed in MetLife Asia’s GA investment portfolio. Mortgage loans (including commercial, agricultural and residential) and real estate equity (including real estate and real estate joint ventures) included in Asia GA AUM (at net asset value, net of deduction for encumbering debt) have been adjusted from carrying value to estimated fair value. At the segment level, intersegment balances (intercompany activity, primarily related to investments in subsidiaries, that eliminate at the MetLife consolidated level) are excluded from Asia GA AUM.<\/p>\n
\nAsia GA AUM (at amortized cost) excludes the following adjustments: (i) unrealized gain (loss) on investments carried at estimated fair value and (ii) adjustments from carrying value to estimated fair value on mortgage loans (including commercial, agricultural and residential) and real estate and real estate joint ventures. Asia GA AUM (at amortized cost) is presented net of related allowance for credit loss.<\/p>\n
Statistical sales information:<\/i><\/b><\/p>\n\n- \nU.S.:<\/p>\n
\n- \nGroup Benefits: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees from recurring premium policy sales of all products.<\/p>\n<\/li>\n
- \nRetirement and Income Solutions: calculated using 10% of single premium deposits and 100% of annualized full-year premiums and fees only from recurring premium policy sales of specialized benefit resources and corporate-owned life insurance.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- \nLatin America, Asia and EMEA: calculated using 10% of single-premium deposits (mainly from retirement products such as variable annuity, fixed annuity and pensions), 20% of single-premium deposits from credit insurance and 100% of annualized full-year premiums and fees from recurring-premium policy sales of all products (mainly from risk and protection products such as individual life, accident & health and group).<\/p>\n<\/li>\n<\/ul>\n
\nSales statistics do not correspond to revenues under GAAP, but are used as relevant measures of business activity.<\/p>\n
The following additional information is relevant to an understanding of MetLife\u2019s performance results and outlook:<\/i><\/b><\/p>\n\n- \nVolume growth, as discussed in the context of business growth, is the period over period percentage change in adjusted earnings available to common shareholders attributable to adjusted premiums, fees and other revenues and assets under management levels, applying a model in which certain margins and factors are held constant. The most significant of such items are underwriting margins, investment margins, changes in equity market performance, expense margins and the impact of changes in foreign currency exchange rates.<\/p>\n<\/li>\n
- \nHolding company cash and liquid assets are held by MetLife, Inc. collectively with other MetLife holding companies and include cash and cash equivalents, short term investments and publicly traded securities excluding assets that are pledged or otherwise committed. Assets pledged or otherwise committed include amounts received in connection with securities lending, repurchase agreements, derivatives, regulatory deposits, the collateral financing arrangement, funding agreements and secured borrowings, as well as amounts held in the closed block.<\/p>\n<\/li>\n
- \nMetLife uses a measure of free cash flow to facilitate an understanding of its ability to generate cash for reinvestment into its businesses or use in non-mandatory capital actions. MetLife defines free cash flow as the sum of cash available at MetLife\u2019s holding companies from dividends from operating subsidiaries, expenses and other net flows of the holding companies (including capital contributions to subsidiaries), and net contributions from debt to be at or below target leverage ratios. This measure of free cash flow is prior to capital actions, such as common stock dividends and repurchases, debt reduction and mergers and acquisitions. Free cash flow should not be viewed as a substitute for net cash provided by (used in) operating activities calculated in accordance with GAAP. The free cash flow ratio is typically expressed as a percentage of annual adjusted earnings available to common shareholders.<\/p>\n<\/li>\n
- \nNotable items reflect the unexpected impact of events that affect MetLife\u2019s results, but that were unknown and that MetLife could not anticipate when it devised its business plan. Notable items also include certain items regardless of the extent anticipated in the business plan, to help investors have a better understanding of MetLife’s results and to evaluate and forecast those results. Notable items represent a positive (negative) impact to adjusted earnings available to common shareholders.<\/p>\n<\/li>\n
- \nWe refer to observable forward yield curves as of a particular date in connection with making our estimates for future results. The observable forward yield curves at a given time are based on implied future interest rates along a range of interest rate durations. This includes the 10-year U.S. Treasury rate which we use as a benchmark rate to describe longer-term interest rates used in our estimates for future results.<\/p>\n<\/li>\n<\/ul>\n
Forward-Looking Statements<\/span><\/p>\n\nThis news release may contain or incorporate by reference information that includes or is based upon forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give expectations or forecasts of future events and do not relate strictly to historical or current facts. They use words and terms such as \u201canticipate,\u201d “are confident,” \u201cassume,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cif,\u201d \u201cintend,\u201d \u201clikely,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d and other words and terms of similar meaning or that are otherwise tied to future periods or future performance, in each case in all derivative forms. They include statements relating to future actions, prospective services or products, future performance or results of current and anticipated services or products, future sales efforts, future expenses, the outcome of contingencies such as legal proceedings, and future trends in operations and financial results.<\/p>\n
\nMany factors determine the results of MetLife, Inc., its subsidiaries and affiliates, and they involve unpredictable risks and uncertainties. Our forward-looking statements depend on our assumptions, our expectations, and our understanding of the economic environment, but they may be inaccurate and may change. MetLife, Inc. does not guarantee any future performance. Our results could differ materially from those MetLife, Inc. expresses or implies in forward-looking statements. The risks, uncertainties and other factors, including those relating to the COVID-19 pandemic, identified in MetLife, Inc.\u2019s filings with the U.S. Securities and Exchange Commission, and others, may cause such differences. These factors include:<\/p>\n
\n\n| \n \n(1)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \neconomic condition difficulties, including risks relating to public health, interest rates, credit spreads, equity, real estate, obligors and counterparties, government default, currency exchange rates, derivatives, climate change and terrorism and security;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(2)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nglobal capital and credit market adversity;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(3)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ncredit facility inaccessibility;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(4)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nfinancial strength or credit ratings downgrades;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(5)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nunavailability, unaffordability, or inadequate reinsurance;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(6)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nstatutory life insurance reserve financing costs or limited market capacity;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(7)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nlegal, regulatory, and supervisory and enforcement policy changes;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(8)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nchanges in tax rates, tax laws or interpretations;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(9)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nlitigation and regulatory investigations;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(10)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nLondon Interbank Offered Rate discontinuation and transition to alternative reference rates;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(11)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nunsuccessful efforts to meet all environmental, social, and governance standards or to enhance our sustainability;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(12)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nMetLife, Inc.\u2019s inability to pay dividends and repurchase common stock;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(13)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nMetLife, Inc.\u2019s subsidiaries\u2019 inability to pay dividends to MetLife, Inc.;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(14)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ninvestment defaults, downgrades, or volatility;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(15)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ninvestment sales or lending difficulties;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(16)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ncollateral or derivative-related payments;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(17)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ninvestment valuations, allowances, or impairments changes;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(18)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nclaims or other results that differ from our estimates, assumptions, or models;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(19)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nglobal political, legal, or operational risks;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(20)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nbusiness competition;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(21)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ntechnological changes;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(22)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ncatastrophes;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(23)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nclimate changes or responses to it;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(24)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ndeficiencies in our closed block;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(25)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ngoodwill or other asset impairment, or deferred income tax asset allowance;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(26)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nimpairment of VOBA, VODA or VOCRA;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(27)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nproduct guarantee volatility, costs, and counterparty risks;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(28)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nrisk management failures;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(29)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ninsufficient protection from operational risks;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(30)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nfailure to protect confidentiality and integrity of data or other cybersecurity or disaster recovery failures;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(31)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \naccounting standards changes;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(32)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nexcessive risk-taking;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(33)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nmarketing and distribution difficulties;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(34)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \npension and other postretirement benefit assumption changes;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(35)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \ninability to protect our intellectual property or avoid infringement claims;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(36)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nacquisition, integration, growth, disposition, or reorganization difficulties;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(37)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nBrighthouse Financial, Inc. separation risks;<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(38)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nMetLife, Inc.\u2019s Board of Directors influence over the outcome of stockholder votes through the voting provisions of the MetLife Policyholder Trust; and<\/p>\n<\/td>\n<\/tr>\n |
\n| \n \n(39)<\/p>\n<\/td>\n | \u00a0<\/td>\n | \n \nlegal- and corporate governance-related effects on business combinations.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n \nMetLife, Inc. does not undertake any obligation to publicly correct or update any forward-looking statements if MetLife, Inc. later becomes aware that such statement is not likely to be achieved. Please consult any further disclosures MetLife, Inc. makes on related subjects in subsequent reports to the U.S. Securities and Exchange Commission.<\/p>\n |